Friends – I hope your MJBizCon was as productive and fun as mine. The conference remains vital, still being the only one that seemingly the entire industry attends (in an industry that still has way too many conferences). It makes for a busy week. At breakfast one morning with a keen observer of the hustle and flow of the cannabis business, my dining partner commented that it seemed to them like a number of the bigger deals lately have been geared towards pushing the NYSE and the Nasdaq to finally open up listing to cannabis companies. Sadly, I can’t take credit for this astute observation, but I’ll expand upon the idea. To me, a number of things have happened lately that are testing the limits that have constrained cannabis companies for years. We’re indeed primarily seeing this in deal activity:
Cannabis Musings - November 29, 2022
Cannabis Musings - November 29, 2022
Cannabis Musings - November 29, 2022
Friends – I hope your MJBizCon was as productive and fun as mine. The conference remains vital, still being the only one that seemingly the entire industry attends (in an industry that still has way too many conferences). It makes for a busy week. At breakfast one morning with a keen observer of the hustle and flow of the cannabis business, my dining partner commented that it seemed to them like a number of the bigger deals lately have been geared towards pushing the NYSE and the Nasdaq to finally open up listing to cannabis companies. Sadly, I can’t take credit for this astute observation, but I’ll expand upon the idea. To me, a number of things have happened lately that are testing the limits that have constrained cannabis companies for years. We’re indeed primarily seeing this in deal activity: